Gilead stock falls after lung cancer study results disappoint
Gilead will discuss the results with regulators and identify whether certain lung cancer patients may still benefit from the drug, known as Trodelvy.
Source: nbcsandiego.com
Page 17 - Michael Yee News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Michael Yee. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Michael Yee Today - Breaking & Trending Today
Eli Lilly shares rise on new DTC service for drugs. Cramer says hold on
The latest catalyst for Eli Lilly is a corporate decision more common in the retail and entertainment industries, not pharmaceuticals.
Source: cnbc.com
US FDA approvals bounce back in 2023, sparking hopes of a biotech recovery
The U.S. Food and Drug Administration approved nearly 50% more novel drugs in 2023 than in 2022, putting it back on pace with historical levels, an improvement analysts and investors said could lead to increased investment in biotech firms. FDA nods for innovative therapies containing an active ingredient or molecule not previously approved, rose to 55 in 2023, up from 37 in 2022 and 51 in 2021. Historical data shows the FDA typically green lights about 45-50 new drugs a year and hit a peak of 59 in 2018.
Source: yahoo.com
US FDA approvals bounce back in 2023, sparking hopes of a biotech recovery
By Manas Mishra and Pratik Jain (Reuters) - The U.S. Food and Drug Administration approved nearly 50% more novel drugs in 2023 than in 2022, putting i...
Source: wsau.com
US FDA approvals bounce back in 2023, sparking hopes of a biotech recovery
By Manas Mishra and Pratik Jain (Reuters) - The U.S. Food and Drug Administration approved nearly 50% more novel drugs in 2023 than in 2022, putting it ...
Source: saltwire.com